Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-05-22 09:00 am Purchase |
2023-05-22 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 3,026,455 3.600% |
3,026,455 (New Position) |
Filing History |
| 2023-02-10 4:15 pm Purchase |
2022-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
Sommadossi Jean-Pierre | 7,474,882 8.800% |
374,883 (+5.28%) |
Filing History |
| 2023-02-10 1:37 pm Purchase |
2022-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
EcoR1 Capital LLC | 6,184,861 7.400% |
808,727 (+15.04%) |
Filing History |
| 2023-02-09 11:07 am Purchase |
2022-12-30 | 13G | Atea Pharmaceuticals, Inc. AVIR |
The Vanguard Group | 6,089,522 7.310% |
307,640 (+5.32%) |
Filing History |
| 2023-02-09 08:23 am Sale |
2023-02-09 | 13G | Atea Pharmaceuticals, Inc. AVIR |
FMR CORP | 11,737,409 14.092% |
-728,000 (-5.84%) |
Filing History |
| 2023-01-24 1:56 pm Purchase |
2022-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
BLACKROCK INC BLK |
8,033,572 9.600% |
2,252,375 (+38.96%) |
Filing History |
| 2022-02-16 4:00 pm Sale |
2021-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
Morningside Venture Investments Limited | 0 0.000% |
-6,634,956 (Position Closed) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
RA Capital Management, L.P. | 0 0.000% |
-5,368,451 (Position Closed) |
Filing History |
| 2022-02-14 3:05 pm Sale |
2021-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
Cormorant Asset Management LP | 1,679,442 2.020% |
-4,731,913 (-73.81%) |
Filing History |
| 2022-02-10 4:15 pm Purchase |
2021-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
Sommadossi Jean-Pierre | 7,099,999 8.400% |
298,335 (+4.39%) |
Filing History |
| 2022-02-09 3:24 pm Purchase |
2021-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
The Vanguard Group | 5,781,882 6.960% |
5,781,882 (New Position) |
Filing History |
| 2022-02-09 09:09 am Purchase |
2022-02-08 | 13G | Atea Pharmaceuticals, Inc. AVIR |
FMR CORP | 12,465,409 14.999% |
3,879,374 (+45.18%) |
Filing History |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
BLACKROCK INC BLK |
5,781,197 7.000% |
5,781,197 (New Position) |
Filing History |
| 2021-12-10 5:08 pm Purchase |
2021-12-01 | 13G | Atea Pharmaceuticals, Inc. AVIR |
EcoR1 Capital LLC | 5,376,134 6.500% |
5,376,134 (New Position) |
Filing History |
| 2021-09-24 5:15 pm Sale |
2021-09-22 | 13D | Atea Pharmaceuticals, Inc. AVIR |
Bain Capital Life Sciences Fund II, L.P. | 3,178,532 3.800% |
-846,856 (-21.04%) |
Filing History |
| 2021-09-03 5:00 pm Sale |
2021-09-01 | 13D | Atea Pharmaceuticals, Inc. AVIR |
Bain Capital Life Sciences Fund II, L.P. | 4,025,388 4.900% |
-757,714 (-15.84%) |
Filing History |
| 2021-04-07 4:31 pm Unchanged |
2021-04-01 | 13G | Atea Pharmaceuticals, Inc. AVIR |
RA Capital Management, L.P. | 5,368,451 6.500% |
0 (Unchanged) |
Filing History |
| 2021-03-10 09:46 am Purchase |
2021-03-09 | 13G | Atea Pharmaceuticals, Inc. AVIR |
FMR CORP | 8,586,035 10.392% |
2,138,344 (+33.16%) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
RA Capital Management, L.P. | 5,368,451 6.500% |
5,368,451 (New Position) |
Filing History |
| 2021-02-16 4:19 pm Purchase |
2020-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
Morningside Venture Investments Limited | 6,634,956 8.030% |
6,634,956 (New Position) |
Filing History |